Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial

Time to recognize three classes of non-inferiority trial margins

(2022) Jeffrey L Saver et al.   Journal of NeuroInterventional Surgery

Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial

(2022) Andrew Bivard et al.   LANCET NEUROLOGY

Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial

(2022) Christopher Elnan Kvistad et al.   LANCET NEUROLOGY

Ethical Justification for Deferral of Consent in the AcT Trial for Acute Ischemic Stroke

(2022) Hannah Faris et al.   STROKE

Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke

(2022) Aristeidis H. Katsanos et al.   JAMA Network Open

Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke

(2020) Bruce C. V. Campbell et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Provincial Door-to-Needle Improvement Initiative Results in Improved Patient Outcomes Across an Entire Population

(2020) Noreen Kamal et al.   STROKE

Do Clinicians Overestimate the Severity of Intracerebral Hemorrhage?

(2019) Elliot J. Tilling et al.   STROKE

Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke

(2019) Adrian M. Burgos et al.   STROKE

Canadian Stroke Best Practice Recommendations for Acute Stroke Management: Prehospital, Emergency Department, and Acute Inpatient Stroke Care, 6th Edition, Update 2018

(2018) JM Boulanger et al.   International Journal of Stroke

Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke

(2018) Bruce C.V. Campbell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial

(2017) Nicola Logallo et al.   LANCET NEUROLOGY

Minimal Clinically Important Difference for Safe and Simple Novel Acute Ischemic Stroke Therapies

(2017) Jessica S. Cranston et al.   STROKE

Minimal sufficient balance randomization for sequential randomized controlled trial designs: results from the ESCAPE trial

(2017) Tolulope T. Sajobi et al.   Trials

Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials

(2016) Xuya Huang et al.   International Journal of Stroke

Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study

(2015) Xuya Huang et al.   LANCET NEUROLOGY

Tenecteplase–Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven Occlusion

(2015) Shelagh B. Coutts et al.   STROKE

The Heidelberg Bleeding Classification

(2015) Rüdiger von Kummer et al.   STROKE

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

(2014) Jonathan Emberson et al.   LANCET

Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic Stroke

(2013) Jeffrey L. Saver et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke

(2012) Mark Parsons et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improving the Reliability of Stroke Disability Grading in Clinical Trials and Clinical Practice

(2010) Jeffrey L. Saver et al.   STROKE

Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke

(2010) E. Clarke Haley et al.   STROKE

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

(2008) Werner Hacke et al.   NEW ENGLAND JOURNAL OF MEDICINE